As the nation’s leading patient organization for headache care, the National Headache Foundation is pleased that the Institute for Clinical and Economic Review (ICER) has determined the new CGRP inhibitors to be cost effective for migraine sufferers who have not obtained satisfactory relief from other therapies. We congratulate and thank the research sponsors, scientists, and volunteers who worked diligently over the last several years to bring this new drug class to fruition. It is our hope that patients with unmet need for migraine relief will be able to access these treatments and will, at long last, find significant improvement in their lives. The NHF looks forward to continuing to elevate the voice of the patient as we address access to care and affordability issues going forward.
– Timothy R. Smith, M.D., R.Ph., the 1st Vice President of the National Headache Foundation
Click here to read more about ICER’s decision on Amgen pricing.